Drug Profile
Research programme: choline kinase inhibitors - Advanced Cancer Therapeutics
Alternative Names: CK 37Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Louisville
- Developer Advanced Cancer Therapeutics; University of Louisville
- Class Small molecules
- Mechanism of Action Choline kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 12 Aug 2010 This programme is still in active development
- 04 Jun 2009 Preclinical trials in Cancer in USA (unspecified route)